The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...

Dr. Knobil currently sits on the boards of Marker Therapeutics, Pliant Therapeutics, Nimbus Therapeutics, KorroBio and Infinant Health. She was previously on the board of Arena Pharmaceuticals ...

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced some great news today, which is that it would be acquired by Novartis AG (NVS) for $7 per share in cash. However, there is room for additional ...

Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash upfront through a subsidiary ...

All that being said, until the actual clinical trial data comes out, it's impossible to say for sure that the drug will be a success, or that Viking Therapeutics stock will go up as far and as ...

A lawyer said he had used the cartoon image of a dragon in a business suit as a logo for his firm, Dragon Lawyers, to symbolize “aggressive representation.” By Michael Levenson A purple dragon ...

LAUSANNE, Switzerland, April 28, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ...

BOSTON, MA, USA I April 25, 2025 I Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful ...

--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7 ...

The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy.

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine ...

FDA approved penpulimab-kcqx for first- and later-line treatment of metastatic non-keratinizing NPC in adults. Phase 3 HARMONi trials showed ivonescimab improved PFS over Keytruda and tislelizumab ...